Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine
Abstract
Patients with HER2+ breast cancer benefit from trastuzumab-containing regimens with improved survival. Adaptive immunity, including cytotoxic T-cell and antibody immunity, is critical to clinical efficacy of trastuzumab. Because Th cells are central to the activation of these antitumor effectors, we reason that HER2 patients treated with trastuzumab may benefit by administering vaccines that are designed to stimulate Th-cell immunity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2123
Entities
People
- Allan B. Dietz
- Amy C Degnim
- Courtney L. Erskine
- Danell Puglisi-knutson
- Douglas Padley
- Glynn Wilson
- Keith L Knutson
- Lavakumar Karyampudi
- Matthew S. Block
- Michael P Gustafson
- Nadine Norton
- Saranya Chumsri
- Timothy J. Hobday
- Toni Kay Mangskau
Organizations
- Mayo Clinic
- National Institutes of Health
- United States Department of Defense